Nivolumab for pediatric malignant peritoneal mesothelioma

Pediatr Blood Cancer. 2023 Feb;70(2):e29892. doi: 10.1002/pbc.29892. Epub 2022 Jul 19.

Authors

Melek Yaman Ortaköylü¹, Sonay İncesoy Özdemir¹, Handan Dinçaslan¹, Nurdan Taçyıldız¹, Ali Ekrem Ünal², Çiğdem Soydal³, Ömer Suat Fitöz⁴, Emel Ünal¹

Affiliations

¹ Division of Pediatric Oncology, Department of Pediatrics, Ankara University, Ankara, Turkey.
² Department of General Surgery, Ankara University, Ankara, Turkey.
³ Department of Nuclear Medicine, Ankara University, Ankara, Turkey.
⁴ Division of Pediatric Radiology, Radiology Department, Ankara University, Ankara, Turkey.

PMID: 35851543
DOI: 10.1002/pbc.29892

No abstract available

Publication types

Letter

MeSH terms

Child
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Mesothelioma* / drug therapy
Mesothelioma* / pathology
Mesothelioma, Malignant* / drug therapy
Nivolumab / therapeutic use

Substances

Nivolumab